We are pleased to welcome Jacob Petersen as the newest member of our Board of Directors. Jacob has since 2018 been head of Stem Cell R&D Unit at Novo Nordisk, being responsible for the entire R&D value chain. He has also been involved in promoting a more international presence for Novo Nordisk Research.
Jacob holds a MSc degree in Biochemistry and a Doctor of Medical Sciences. Since 2010 he has been an adjunct professor in biomedicine at Copenhagen University Medical Faculty.
With his very relevant R&D background he will supplement the Board and be part of the journey of bringing new enzymes to the markets including supporting Novo Nordisk´s own pipeline:
“I look very much forward to being part of the Board of Directors and supporting Novo Nordisk Pharmatech on the journey into new growth areas delivering superior ingredients to the regenerative market. At the same time, it is exciting to be part of further elevating the existing product portfolio, which holds some fantastic products.”
The Board of Directors is responsible for the overall strategic management of the company and supervises the performance of the company. It consists of six people including two employee elected members from Novo Nordisk Pharmatech. Jacob Petersen joined the board on June 1 as the successor of Ulla Grove Krogsgaard Thomsen.
You can see all Board members here.